Penny Stocks To Watch Before November
One of the most consistently resilient industries in the stock market today is biotech. With that penny stocks have played a relatively larger role especially this year. The coronavirus has also had a hand in propelling a number of these small-cap biotech names. Obviously, one of the main reasons had to do with a mad dash for companies to find a potential vaccine. Aided by billions of dollars from the government, companies of all shapes and sizes shifted focus from main pipelines to a coronavirus cure.
While we still don’t have a vaccine, what we do have are millions of new, informed traders. This year saw millions of novice market participants try their hands at stocks. Partially due to pandemic lockdown requirements, this new bunch of traders flew to platforms like Webull and Robinhood to trade penny stocks and get in on the action.
As volatility became the new addiction, the trend switched from biotech coronavirus stocks to simply biotech penny stocks, in general. Thanks to things like cutting edge research and a general climate based on speculation, most biotech stocks under $5 offered that volatility that most day traders seek out.
Biotech Penny Stocks To Watch:
- GT Biopharma Inc. (GTBP Stock Report)
- miRagen Therapeutics Inc. (MGEN Stock Report)
- vTv Therapeutics Inc. (VTVT Stock Report)
- Amarin Corporation (AMRN Stock Report)
- Sesen Bio Inc. (SESN Stock Report)
The remainder of the week might be focused on technology. But heading into a new month next week, there are plenty of things to keep in mind. Everything from data readouts to industry and investor conferences, which can all become their own catalysts as well. So with one more day left before all that, here’s a list of penny stocks to watch heading into the final session of October.
Biotech Penny Stocks To Watch #1: GT Biopharma Inc.
GT Biopharma Inc. (OTC:GTBP) is one of the biotech penny stocks that has experienced a strong year in 2020 and it hasn’t been based on coronavirus. The company focuses on immunotherapy. While there’ve been plenty of developments over the last few months, it’s been the last 45 days that has built more up interest in the company.
In its last update, GT Biopharma announced the publication of “NK-Cell-Mediated Targeting of Various Solid Tumors Using a B7-H3 Tri-Specific Killer Engager In Vitro and In Vivo”. This was in the journal Cancers. B7H3 is highly expressed on the surface of several types of cancers and when targeted by the company’s TriKE™ the findings were favorable. GT found that it has the potential to enhance natural killer cell immunotherapy in solid tumor settings supporting further clinical development.
But it hasn’t just been TriKE™ as a standalone. This is actually the company’s treatment platform and the one its lead candidate, GTB-3550 is built on. GTB-3550 is GT Biopharma’s candidate for treating acute myeloid leukemia and has already shown a favorable response in Dose Level 3 of its Phase I/II trial. Furthermore, interim data was chosen for presentation at the upcoming ASH conference. GT also said that an abstract will also be published online in the November supplemental issue of the journal Blood. The first publication will be in the online ASH meeting program on November 5, 2020.
Given the surge of interest growing in the market, GTBP stock has managed to climb significantly over the last month. What will November bring?
Biotech Penny Stocks To Watch #2: miRagen Therapeutics Inc.
We just recently began covering miRagen Therapeutics Inc. (NASDAQ:MGEN) this week. On October 25th we discussed it among a list of other penny stocks on Robinhood to watch. The main focus for taking a closer look at MGEN after an uptick in trading activity late last week. One thing we preach is research over the weekend. In this case, research certainly was worth it. Since Monday (the article was on Sunday), MGEN stock has climbed from around $0.50 to highs so far of $1.50; up 200%+ considering aftermarket trading on Thursday.
Read More
- Looking For The Best Penny Stocks To Buy Now? 3 Tech Names To Know
- Does Your List Of Penny Stocks Have These Trending Names On It?
Earlier this week, the company announced that it had acquired Viridian Therapeutics in a play to gain access to its thyroid eye disease treatment. Worldwide rights to develop and commercialize VRDN-001 for all non-oncology indications that do not use radiopharmaceuticals, including the treatment of thyroid eye disease, were exclusively licensed by Viridian from ImmunoGen, Inc.
Why is MGEN stock still on the radar right now? Aside from the fact that the company’s stock continues holding recent gains, new filings came out on Thursday showing a 9.5% stake by none other than Steven Cohens Point72 Asset Management. It will be interesting to see what happens next as several key developments have definitely extended drastically this week. Is a pullback in store or are new 52-week highs in store?
Biotech Penny Stocks To Watch #3: vTv Therapeutics Inc.
vTv Therapeutics Inc. (NASDAQ:VTVT) saw one of its most active trading days in months, Thursday. The biggest question mark for VTVT stock is whether it will be a buy the rumor/sell the news event or not on Friday. The company is set to present preliminary data on the baseline characteristics of participants in its Phase 2 Alzheimer’s drug study next week. While topline results aren’t expected until December this could shed some light on how the trial is going.
November 4th is the date to keep in mind. vTv presents at the 13th Clinical Trials on Alzheimer’s Disease Digital Event. This trial is treating Alzheimer’s patients also suffering from type 2 diabetes. In light of Thursday’s move in VTVT stock, it will be interesting to see if the momentum continues heading into next week’s presentation.
Biotech Penny Stocks To Watch #4: Amarin Corporation
Amarin Corporation (NASDAQ:AMRN) has been an interesting story to follow to say the least. Shares dropped from over $7 to under $5 in early September after a ruling on its VASCEPA ANDA patent litigation. The outcome was clearly unfavorable as you’ll see on the AMRN stock chart. However, the company’s most recent developments could shed some positive light on the company this month.
Amarin presented new data of its REDUCE-IT study showcasing the potential of VASCEPA®. The principal investigator of REDUCE-IT Dr. Deepak L. Bhatt said, “The statistically significant substantial benefit in reduced coronary revascularization procedures seen as early as 11 months provides clinicians with a potential additional intervention in a patient population for whom time is of the essence.”
A follow on to this was reported this week at another conference, American Society of Nephrology Kidney Week 2020. Further details will be presented at the American Heart Association’s Scientific Sessions in November.
Biotech Penny Stocks To Watch #5: Sesen Bio Inc.
Sesen Bio Inc. (NASDAQ:SESN) has been steadily holding gains for most of October. It had pulled back slightly from highs. October was the first month that had several key developments that helped boost momentum. The company selected Cardinal Health as its exclusive provider for third-party logistics and specialty pharmaceutical distribution services. These were related to the commercial distribution of its Vicineum in the United States. Vicineum, also known as VB4-845, is currently in the follow-up stage of a Phase 3 registration trial treating non-muscle invasive bladder cancer.
[Read More] Are Penny Stocks Worth It? 4 For Your Watch List This Week
This week Sesen completed a successful pre-submission meeting with the European Medicines Agency for Vicineum in Europe. Dr. Thomas Cannell, president and chief executive officer of Sesen Bio explained, “Europe represents one of the largest regions in terms of unmet need for patients with NMIBC, and we appreciate the agency’s guidance and confidence in Sesen Bio to pursue an MAA submission for approval of Vicineum.”
Sesen said that it aims to complete all necessary pre-submission activities with the European Medicines Agency by the end of 2020.
Pursuant to an agreement between Midam Ventures LLC and GT Biopharma (GTBP), GT Biopharma is required to pay $200,000 per month for 4 months of services, $400,000 of which has already been paid for 2 months of services (first and last month) for a period from September 22, 2020 to January 22, 2021. We may buy or sell additional shares of GT Biopharma (GTBP) in the open market at any time, including before, during or after the Website and Information, to provide public dissemination of favorable Information about GT Biopharma (GTBP).
